Legal & General Group’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.25M | Buy |
60,875
+10,376
| +21% | +$554K | ﹤0.01% | 1754 |
|
|
2025
Q1 | $2.04M | Buy |
50,499
+419
| +0.8% | +$17K | ﹤0.01% | 1911 |
|
|
2024
Q4 | $1.39M | Sell |
50,080
-196
| -0.4% | -$5.45K | ﹤0.01% | 2130 |
|
|
2024
Q3 | $1.44M | Sell |
50,276
-1,101
| -2% | -$31.6K | ﹤0.01% | 2103 |
|
|
2024
Q2 | $1.21M | Buy |
51,377
+1,450
| +3% | +$34K | ﹤0.01% | 2133 |
|
|
2024
Q1 | $1.26M | Buy |
49,927
+6,790
| +16% | +$172K | ﹤0.01% | 2114 |
|
|
2023
Q4 | $1.01M | Sell |
43,137
-112
| -0.3% | -$2.62K | ﹤0.01% | 2208 |
|
|
2023
Q3 | $2.19M | Buy |
43,249
+2,885
| +7% | +$146K | ﹤0.01% | 1854 |
|
|
2023
Q2 | $1.88M | Buy |
40,364
+10,977
| +37% | +$513K | ﹤0.01% | 1957 |
|
|
2023
Q1 | $1.12M | Buy |
29,387
+16,158
| +122% | +$618K | ﹤0.01% | 2109 |
|
|
2022
Q4 | $725K | Buy |
13,229
+2,993
| +29% | +$164K | ﹤0.01% | 2239 |
|
|
2022
Q3 | $349K | Buy |
10,236
+2,758
| +37% | +$94K | ﹤0.01% | 2439 |
|
|
2022
Q2 | $71K | Buy |
7,478
+569
| +8% | +$5.4K | ﹤0.01% | 2931 |
|
|
2022
Q1 | $98K | Hold |
6,909
| – | – | ﹤0.01% | 2875 |
|
|
2021
Q4 | $146K | Buy |
6,909
+42
| +0.6% | +$888 | ﹤0.01% | 2822 |
|
|
2021
Q3 | $153K | Buy |
6,867
+3,088
| +82% | +$68.8K | ﹤0.01% | 2755 |
|
|
2021
Q2 | $93K | Buy |
3,779
+1,421
| +60% | +$35K | ﹤0.01% | 2761 |
|
|
2021
Q1 | $69K | Sell |
2,358
-72
| -3% | -$2.11K | ﹤0.01% | 2725 |
|
|
2020
Q4 | $63K | Hold |
2,430
| – | – | ﹤0.01% | 2735 |
|
|
2020
Q3 | $75K | Buy |
2,430
+586
| +32% | +$18.1K | ﹤0.01% | 2565 |
|
|
2020
Q2 | $46K | Buy |
1,844
+564
| +44% | +$14.1K | ﹤0.01% | 2750 |
|
|
2020
Q1 | $27K | Buy |
1,280
+370
| +41% | +$7.81K | ﹤0.01% | 2793 |
|
|
2019
Q4 | $20K | Buy |
910
+151
| +20% | +$3.32K | ﹤0.01% | 3179 |
|
|
2019
Q3 | $17K | Buy |
+759
| New | +$17K | ﹤0.01% | 3179 |
|